Literature DB >> 33298207

Clinical consequences of contaminated blood cultures in adult hospitalized patients at an institution utilizing a rapid blood-culture identification system.

Sidra Liaquat1, Lorena Baccaglini1, Gleb Haynatzki2, Sharon J Medcalf1, Mark E Rupp3.   

Abstract

OBJECTIVE: To assess the clinical impact of contaminated blood cultures in hospitalized patients during a period when rapid diagnostic testing using a FilmArray Blood Culture Identification (BCID) panel was in use.
DESIGN: Retrospective cohort study.
SETTING: Single academic medical center. PARTICIPANTS: Patients who had blood culture(s) performed during an admission between June 2014 and December 2016.
METHODS: Length of hospital stay and days of antibiotic therapy were assessed in relation to blood-culture contamination using generalized linear models with univariable and multivariable analyses.
RESULTS: Among 11,474 patients who had blood cultures performed, the adjusted mean length of hospital stay for patients with contaminated blood-culture episodes (N = 464) was 12.3 days (95% confidence interval [CI], 11.4-13.2) compared to 11.5 days (95% CI, 11.0-11.9) for patients (N = 11,010) with negative blood-culture episodes (P = .032). The adjusted mean durations of antibiotic therapy for patients with contaminated and negative blood-culture episodes were 6.0 days (95% CI, 5.3-6.7) and 5.2 days (95% CI, 4.9-5.4), respectively (P = .011).
CONCLUSIONS: Despite the use of molecular-based, rapid blood-culture identification, contamination of blood cultures continues to result in prolonged hospital stay and unnecessary antibiotic therapy in hospitalized patients.

Entities:  

Year:  2020        PMID: 33298207     DOI: 10.1017/ice.2020.1337

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  2 in total

Review 1.  Clinical Approach to Nosocomial Bacterial Sepsis.

Authors:  Pramod Reddy
Journal:  Cureus       Date:  2022-08-30

2.  Antibacterial use in the age of SARS-CoV-2.

Authors:  Kathleen E Angell; James V Lawler; Angela L Hewlett; Mark E Rupp; Scott J Bergman; Trevor C Van Schooneveld; M Jana Broadhurst; David M Brett-Major
Journal:  JAC Antimicrob Resist       Date:  2021-06-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.